A six-month study at the University of Auckland revealed that while feijoa fruit powder did not improve blood sugar control in adults with prediabetes, it was linked to a significant decrease in systolic blood pressure, prompting calls for further research…
A comprehensive review highlights the complex and tissue-specific influence of the FTO gene on metabolism, obesity, and insulin resistance, calling for cautious interpretation of its role in disease pathways. A detailed review in Dove Press argues that the fat mass…
Research indicates that the nutrient balance and processing of breakfast staples like eggs and toast with peanut butter significantly impact blood sugar and blood pressure, with added salt and fats playing a critical role. For people watching blood sugar or…
Christian author Jackie Hill Perry shares how her unexpected Type 1 diabetes diagnosis in 2025 prompted a profound reevaluation of her faith and dependence on God, inspiring discussions on suffering and divine sovereignty. Jackie Hill Perry has described how a…
As Navratri approaches, experts emphasise the importance of personalised, cautious fasting practices amidst concerns over health risks and the myth of detoxification, urging adherence to modern medical guidance for safer celebrations. As Sharad Navratri approaches and the weather turns cooler…
Oscar-winning actor Octavia Spencer reveals how a routine medical checkup in her 30s uncovered silent diabetes and high blood pressure, prompting a lifestyle overhaul and raising awareness about preventive health. Octavia Spencer has revealed that a routine medical checkup in…
With over 40 million adults living with diabetes in the US, health authorities emphasise the importance of recognising symptoms and timely screening to prevent complications amidst rising prevalence and risk factors. More than 40 million adults in the United States…
Lilly’s oral GLP-1 drug Foundayo, orforglipron, demonstrated notable projected reductions in 10-year risks of type 2 diabetes and cardiovascular disease in a Phase 3 trial, highlighting its promise beyond weight management. Eli Lilly says its once-daily oral GLP-1 treatment Foundayo,…
New analyses from the Phase 3 ATTAIN-1 trial suggest that Eli Lilly’s oral GLP-1 medicine Foundayo could lower predicted long-term risks of type 2 diabetes and cardiovascular disease, marking a potential breakthrough in obesity and cardiometabolic treatment. Eli Lilly’s oral…
A 78-year-old man with long-standing type 2 diabetes has significantly improved his condition after adopting a low-fat, whole-food, plant-based diet, shedding nearly 60 pounds and reducing medications, highlighting a potential shift in diabetes care approaches. At 78, Mike says he…
